Hundreds of compounds have been reported to inhibit NF‐κB, but their clinical efficacy has so far been unsatisfactory except in certain types of lymphoma and leukaemia [12], possibly due to the lack of tumour cell specificity in most current NF‐κB targeting strategies. Here, NFKB1 is linked to leukemia.